These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37265114)

  • 1. Photo-Uncaging by C(sp
    Kaye EG; Mirabi B; Lopez-Miranda IR; Dissanayake KC; Banerjee U; Austin M; Lautens M; Winter AH; Beharry AA
    J Am Chem Soc; 2023 Jun; 145(23):12518-12531. PubMed ID: 37265114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
    Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
    Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Carbon-Carbon Bond Cleavage-Based Prodrug Activation Strategy Applied to β-Lapachone for Cancer-Specific Targeting.
    Gong Q; Li X; Li T; Wu X; Hu J; Yang F; Zhang X
    Angew Chem Int Ed Engl; 2022 Oct; 61(40):e202210001. PubMed ID: 35938884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
    Qadir MI; Iqbal MS; Khan R
    Curr Cancer Drug Targets; 2022; 22(7):537-540. PubMed ID: 35490325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones.
    Frydman B; Marton LJ; Sun JS; Neder K; Witiak DT; Liu AA; Wang HM; Mao Y; Wu HY; Sanders MM; Liu LF
    Cancer Res; 1997 Feb; 57(4):620-7. PubMed ID: 9044837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding Transition Metal-Mediated Bioorthogonal Decaging to Include C-C Bond Cleavage Reactions.
    Dal Forno GM; Latocheski E; Beatriz Machado A; Becher J; Dunsmore L; St John AL; Oliveira BL; Navo CD; Jiménez-Osés G; Fior R; Domingos JB; Bernardes GJL
    J Am Chem Soc; 2023 May; 145(19):10790-10799. PubMed ID: 37133984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
    Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
    Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
    Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization, reactivity and photosensitizing properties of the triplet excited state of alpha-lapachone.
    Netto-Ferreira JC; Lhiaubet-Vallet V; Bernardes BO; Ferreira AB; Miranda MA
    Phys Chem Chem Phys; 2008 Nov; 10(44):6645-52. PubMed ID: 18989476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
    Pink JJ; Planchon SM; Tagliarino C; Varnes ME; Siegel D; Boothman DA
    J Biol Chem; 2000 Feb; 275(8):5416-24. PubMed ID: 10681517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled masking and targeted release of redox-cycling ortho-quinones via a C-C bond-cleaving 1,6-elimination.
    Dunsmore L; Navo CD; Becher J; de Montes EG; Guerreiro A; Hoyt E; Brown L; Zelenay V; Mikutis S; Cooper J; Barbieri I; Lawrinowitz S; Siouve E; Martin E; Ruivo PR; Rodrigues T; da Cruz FP; Werz O; Vassiliou G; Ravn P; Jiménez-Osés G; Bernardes GJL
    Nat Chem; 2022 Jul; 14(7):754-765. PubMed ID: 35764792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis.
    Lien YC; Kung HN; Lu KS; Jeng CJ; Chau YP
    Histol Histopathol; 2008 Nov; 23(11):1299-308. PubMed ID: 18785111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer therapy with beta-lapachone.
    Pardee AB; Li YZ; Li CJ
    Curr Cancer Drug Targets; 2002 Sep; 2(3):227-42. PubMed ID: 12188909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis.
    Gomes CL; de Albuquerque Wanderley Sales V; Gomes de Melo C; Ferreira da Silva RM; Vicente Nishimura RH; Rolim LA; Rolim Neto PJ
    Phytochemistry; 2021 Jun; 186():112713. PubMed ID: 33667813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
    Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
    PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
    Dong Y; Chin SF; Blanco E; Bey EA; Kabbani W; Xie XJ; Bornmann WG; Boothman DA; Gao J
    Clin Cancer Res; 2009 Jan; 15(1):131-9. PubMed ID: 19118040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.